Skip to main content

Table 3 Results of analyses of lipoprotein fraction and LDL-MI after pemafibrate treatment

From: Pemafibrate decreases triglycerides and small, dense LDL, but increases LDL-C depending on baseline triglycerides and LDL-C in type 2 diabetes patients with hypertriglyceridemia: an observational study

Characteristic Baseline Post-dose
Increased LDL-C group (group I)
(n = 21)
No LDL-C increase group (group NI)
(n = 21)
P* Increased LDL-C group (group I)
(n = 20)
No LDL-C increase group (group NI)
(n = 20)
P*
Lipoprotein fraction (PAG electrophoresis)
HDL, mean (SD), % 21.0 (7.8) 19.0 (5.2) ** 0.3358 20.7 (5.6) 23.6 (5.2) 0.0907
LDL, mean (SD), % 34.2 (14.5)*** 46.4 (6.5) 0.0011 47.8 (10.9) 44.9 (5.5) 0.2867
Midband, mean (SD), % 18.5 (8.5) 12.5 (6.4) 0.0141 14.7 (6.6) 14.4 (8.8) 0.9034
VLDL, mean (SD), % 28.2 (10.8) *** 22.0 (5.2) ** 0.0234 17.1 (6.3) 17.3 (6.2) 0.9399
LDL-MI, median (IQR) 0.421 (0.391–0.450) **** 0.354 (0.341–0.396) < 0.0001 0.367 (0.344–0.389) 0.348 (0.331–0.380) 0.2339
  1. P<0.05 was considered statistically significant. *, Statistical analysis between 2 groups was done using the t-test or Mann-Whitney U test. **, P<0.02 vs. group NI at post-dose (t-test). ***, P<0.002 vs. group I at post-dose (t-test). ****, P=0.0002 vs. group I at post-dose (Mann-Whitney U test). PAG Polyacrylamide gel, LDL-MI LDL migration index, LDL-C Low density lipoprotein cholesterol, IQR Inter-quartile range, HDL High density lipoprotein, LDL Low density lipoprotein, VLDL Very-low density lipoprotein